BioStable Science & Engineering, Inc. announced today that it has completed a direct de novo application to the U.S. Food and Drug Administration (FDA) for Class II designation of the HAART 300 Aortic Annuloplasty Device. Submission of the de novo request is an important milestone in BioStable’s efforts to bring the potential benefits of valve repair to U.S. patients suffering with aortic valve insufficiency. (read more)
GenomOncology today announced the recent extension of the GO Clinical Workbench™ to support Hematologic cancer testing and decision support.
Molecular diagnostic laboratories across the country have used GenomOncology’s workbench for their solid tumor testing needs for over two years. (read more)
Satchel Health, a company that uses connected devices to provide telehealth offerings to post-acute care providers, has raised just over $1 million in angel investments. The round was led by NueCura Partners, a healthcare-focused angel firm in Nashville, Tennessee, where Satchel is also based. (read more)
In the two years since it launched proprietary software solutions for next-generation sequence data analysis, GenomOncology has expanded its platform to include a number of additional applications that cater to a much broader range of analysis and interpretation needs. (read more)
Genomics England is partnering with GenomOncology, LLC (GO) to utilize the GO Knowledge Management System (GO KMS) as a tool for clinical reporting enablement. (read more)
NuSirt Biopharma, a company dedicated to improving the lives of those with chronic metabolic diseases, and One Way Liver S.L. (OWL Metabolomics), a leader in the field of metabolomics and liver diseases diagnostics, today announced they have initiated a strategic partnership to develop novel diagnostic tools for ongoing drug evaluation trials for NuSirt’s fatty liver drug research candidate, NS-0200. (read more)
It was more than a month before Lucy Josserand, born weighing 2 pounds, 11.5 ounces, was able to see and enjoy the comforts of her own nursery in her Texarkana home.
But Lucy’s parents never left her side thanks to the help of Angel Eye Camera Systems.
The Innovation Institute announced today that it has acquired controlling interest in Nashville-based TriStar Health Partners, LLC, to advance its healthcare-focused investment management platform, the critical third element of The Institute’s business model. (read more)
“Pathline Emerge takes a multi-disciplinary approach to evaluate specific types of cancer to support personalized medicine. Our full-service pathology laboratory was one of the first to obtain New York State approval for clinical NGS testing. As the demand for NGS testing and personalized medicine continues to grow and more information becomes available, better solutions are needed to quickly and thoroughly analyze the burgeoning amounts of data,” said Michael Lorenzo, VP of Operations at Pathline Emerge. “With this in mind, Pathline Emerge partnered with GenomOncology for a software solution, which allows us to streamline our workflow and deliver robust clinical reports. The GO Clinical Workbench will allow Pathline Emerge to scale efficiently while also maintaining compliance.” (read more)
When Kelly Gallagher left her newborn twins at Holy Redeemer Hospital two years ago, she sobbed as she headed home to Montgomery Township.
It didn’t feel right, she said, to be leaving her premature baby boys — Connor and Curran, born at 32 weeks instead of the normal 38 to 40 weeks — in the care of strangers, even if they were experts in the care of preemies. (read more)